SC
FOLD

Sagefield Capital’s Amicus Therapeutics FOLD Stock Holding History

Sagefield Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Buy
+1,021,016
New +$14.6M 1.06% 27

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Sagefield Capital's FOLD Position: Q1 2026 in Review

Sagefield Capital opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 1,021,016 shares worth $14.8M. The stake represents 1.06% of the portfolio and ranks #27 among its holdings.

298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Sagefield Capital held 1,021,016 shares of Amicus Therapeutics worth $14.8M as of Q1 2026.
  • Amicus Therapeutics was a new Sagefield Capital position in Q1 2026.
  • Amicus Therapeutics made up 1.06% of Sagefield Capital's portfolio in Q1 2026, its #27 holding.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Sagefield Capital's 13F filing for Q1 2026, filed 15 May 2026.